Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02457884
Other study ID # 12131601
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2015
Est. completion date June 2018

Study information

Verified date February 2019
Source The Hong Kong Polytechnic University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetic macular oedema (DMO) is a sight-threatening problem for diabetic patient who has swelling in macula. Patients with DMO can receive laser treatment and achieve good acuity finally. However, some patients still have difficulties in reading even after proper treatment.

In this project, the investigators aimed to explore the effectiveness of different training paradigms in improving reading performance in patients with DMO.


Description:

Patients with diabetic macular oedema (DMO), after receiving laser photocoagulation, achieved good outcomes in distance acuity. However, some patients, particularly those developing parafoveal scotoma, still had difficulty in reading. Inability to read or reading very slowly leads to the potential loss of job, as well as the enjoyment of reading for leisure.

In this study, the investigators aimed to investigate the effectiveness of reading rehabilitation using perceptual learning paradigms in enhancing reading performance in patients with reading difficulties due to DMO. Also, the fundamental mechanisms explaining the reading problems in patients with DMO reading Chinese will be examined.

The investigators hypothesize that the perceptual training would show an improvement in reading. The investigators' primary hypothesis is that temporal visual processing speed and spatial visual span will be improved after perceptual training. The investigators' secondary hypothesis is that the reading speed and fixation stability will be improved after training.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date June 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria:

- Able to read Chinese.

- No formal vision rehabilitation training in reading after vision loss

- Diagnosis of diabetic macular oedema (DMO) and had previous treatment with laser and / or intravitreal injections

- Reasonable control of blood glucose level (HbA1c <10) to minimize the impact of vision fluctuation

- Education level of 6 years or more (primary school or above)

Exclusion Criteria:

- Receive any types of eye treatments other than those mentioned above

- Any diagnosed ocular diseases other than DMO

- Severe medical problems or self reported neurological or cognitive disorders

- Serious hearing impairment

- Previously attended vision rehabilitation clinic

Study Design


Intervention

Other:
Temporal Group
Visual Processing Training
Spatial Group
Spatial visual span training
Combined Group
Visual processing speed and spatial visual span training
Control Group
Leisure reading activities

Locations

Country Name City State
China Allen MY Cheong Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The Hong Kong Polytechnic University The University of Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in visual processing speed Using trigrams to measure the character-recognition accuracy while characters are presented at different exposure times Change from baseline at week 6 and change from baseline at week 12 week
Primary Change in visual span size Using trigrams to measure the character-recognition accuracy while characters are presented at different positions Change from baseline at week 6 and change from baseline at week 12 week
Secondary Change in reading performance Measured in three different ways for Chinese:
Rapid serial visual presentation (RSVP)
Sentence reading (MNREAD)
Passage reading (IReST)
Change from baseline at week 6 and change from baseline at week 12 week
Secondary Change in fixation stability Fixation stability will be measured by MP-1 microperimeter. Change from baseline at week 6 and change from baseline at week 12 week
Secondary Change in Chinese version of Impact of Visually Impaired (C-IVI) measure Self evaluated instrument to measure vision related restriction of participation in daily living. Change from baseline at week 6 and change from baseline at week 12 week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04576689 - Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy Phase 2
Completed NCT02554747 - Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa N/A
Withdrawn NCT02309476 - Sub-threshold Photocoagulation of Diabetic Macular Oedema N/A
Terminated NCT02207712 - Noctura400 Treatment for Diabetic Retinopathy (CANDLE) N/A
Completed NCT00148330 - Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study Phase 2/Phase 3
Completed NCT03495765 - To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus Phase 3
Completed NCT00167518 - Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) Phase 2/Phase 3
Completed NCT01787669 - Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema Phase 2
Completed NCT01175070 - Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Phase 4
Terminated NCT00427986 - Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema N/A
Completed NCT00333671 - Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema) N/A
Completed NCT02731911 - Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Completed NCT00148265 - A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema Phase 2/Phase 3
Completed NCT02181400 - Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema N/A